Intensive care management of the patient with cystic fibrosis

Journal of Intensive Care Medicine

Volumn 23, Issue 3, 2008, Pages 159-177

  Kremer, Ted M ^a   Zwerdling, Robert G ^a   Michelson, Peter H ^b   O'Sullivan, Brian P ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Cystic fibrosis; End of life care; Extrapulmonary complications; Lung transplantation; Pseudomonas aeruginosa

Indexed keywords

ACETYLCYSTEINE; AMIKACIN; AMINOCAPROIC ACID; AZTREONAM; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CEFOXITIN; CEFTAZIDIME; CHLORAMPHENICOL; CLARITHROMYCIN; COTRIMOXAZOLE; DORNASE ALFA; ETHAMBUTOL; IBUPROFEN; IMIPENEM; LINEZOLID; MACROGOL 3350; MACROLIDE; MEROPENEM; MINOCYCLINE; MUCOLYTIC AGENT; NAFCILLIN; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE; RIFAMPICIN; STREPTOMYCIN; TOBRAMYCIN; TRANEXAMIC ACID; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VANCOMYCIN; VITAMIN K GROUP;

AIRWAY OBSTRUCTION; ARTIFICIAL EMBOLISM; ARTIFICIAL VENTILATION; BREATHING EXERCISE; BRONCHUS HYPERREACTIVITY; CYSTIC FIBROSIS; DEATH; DIABETES MELLITUS; ENTEROPATHY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GROWTH INHIBITION; HEMOPTYSIS; HEPATOBILIARY DISEASE; HUMAN; INTENSIVE CARE; KIDNEY DISEASE; LIVER DISEASE; LUNG INFECTION; LUNG TRANSPLANTATION; PANCREAS DISEASE; PATIENT SELECTION; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SURVIVAL RATE; TERMINAL CARE;

CYSTIC FIBROSIS; HUMANS; INTENSIVE CARE; LUNG DISEASES; LUNG TRANSPLANTATION; RESPIRATORY INSUFFICIENCY;

EID: 43449095448     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066608315679     Document Type: Review

References (153)

1. Rosenstein BJ, Cutting GR The diagnosis of cystic fibrosis: a consensus statement. cystic fibrosis foundation consensus panel. J Pediatr. 1998 ; 132: 589-595.
2. Anon. 2004 Annual Data Report to the Center Directors. Bethesda, MD: The Cystic Fibrosis Foundation ; 2005.
3. Davis PB Cystic fibrosis since 1938. Am J Respir Crit Care Med. 2006 ; 173: 475-482.
4. Gibson RL, Burns JL, Ramsey BW Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003 ; 168: 918-951.
5. Rowe SM, Miller S., Sorscher EJ Cystic fibrosis. N Engl J Med. 2005 ; 352: 1992-2001.
6. Koehler DR, Downey GP, Sweezey NB, Tanswell AK, Hu J. Lung inflammation as a therapeutic target in cystic fibrosis. Am J Respir Cell Mol Biol. 2004 ; 31: 377-381.
7. Gibson LE, Cooke RE A test for concentration of electrolytes in sweat of cystic fibrosis of the pancreas utilizing pilocarpine iontophoresis. Pediatrics. 1959 ; 23: 545-549.
8. Beauchamp M., Lands LC Sweat-testing: a review of current technical requirements. Pediatr Pulmonol. 2005 ; 39: 507-511.
9. Groman JD, Meyer ME, Wilmott RW, Zeitlin PL, Cutting GR Variant cystic fibrosis phenotypes in the absence of CFTR mutations. N Engl J Med. 2002 ; 347: 401-407.
10. Farrell PM, Kosorok MR, Laxova A., et al. Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. N Engl J Med. 1997 ; 337: 963-969.
11. Rosenfeld M. Overview of published evidence on outcomes with early diagnosis from large US observational studies. J Pediatr. 2005 ; 147: S11 - S14.
12. Engelhardt JF, Yankaskas JR, Ernst SA, et al. Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nat Genet. 1992 ; 2: 240-248.
13. Jayaraman S., Joo NS, Reitz B., Wine JJ, Verkman AS Submucosal gland secretions in airways from cystic fibrosis patients have normal [Na(+)] and pH but elevated viscosity. Proc Natl Acad Sci U S A. 2001 ; 98: 8119-8123.
14. Knowles MR, Boucher RC Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest. 2002 ; 109: 571-577.
15. Robinson M., Bye PTB. Mucociliary clearance in cystic fibrosis. Pediatr Pulmonol. 2002 ; 33: 293-306.
16. Khan TZ, Wagener JS, Bost T., Martinez J., Accurso FJ, Riches DW Early pulmonary inflammation in infants with cystic fibrosis. [see comment]. Am J Respir Crit Care Med. 1995 ; 151: 1075-1082.
17. Muhlebach MS, Stewart PW, Leigh MW, Noah TL Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med. 1999 ; 160: 186-191.
18. Ogrinc G., Kampalath B., Tomashefski JF Jr. Destruction and loss of bronchial cartilage in cystic fibrosis. Hum Pathol. 1998 ; 29: 65-73.
19. Durieu I., Peyrol S., Gindre D., Bellon G., Durand DV, Pacheco Y. Subepithelial fibrosis and degradation of the bronchial extracellular matrix in cystic fibrosis. Am J Respir Crit Care Med. 1998 ; 158: 580-588.
20. Armstrong DS, Grimwood K., Carlin JB, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med. 1997 ; 156: 1197-1204.
21. Lyczak JB, Cannon CL, Pier GB Lung infections associated with cystic fibrosis. Clin Microbiol Rev. 2002 ; 15: 194-222.
22. Registry CFFP. 2001 Annual Data Report to the Center Directors. Bethesda, MD: Cystic Fibrosis Foundation ; 2002.
23. Koch C. Early infection and progression of cystic fibrosis lung disease. Pediatr Pulmonol. 2002 ; 34: 232-236.
24. Maselli JH, Sontag MK, Norris JM, MacKenzie T., Wagener JS, Accurso FJ Risk factors for initial acquisition of pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening. [see comment]. Pediatr Pulmonol. 2003 ; 35: 257-262.
25. Anwar H., Dasgupta M., Lam K., Costerton JW Tobramycin resistance of mucoid pseudomonas aeruginosa biofilm grown under iron limitation. J Antimicrob Chemother. 1989 ; 24: 647-655.
26. Hodges NA, Gordon CA Protection of pseudomonas aeruginosa against ciprofloxacin and beta-lactams by homologous alginate. Antimicrob Agents Chemother. 1991 ; 35: 2450-2452.
27. Nichols WW, Dorrington SM, Slack MP, Walmsley HL Inhibition of tobramycin diffusion by binding to alginate. Antimicrob Agents Chemother. 1988 ; 32: 518-523.
28. Li Z., Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA. 2005 ; 293: 581-588.
29. Griese M., Muller I., Reinhardt D. Eradication of initial pseudomonas aeruginosa colonization in patients with cystic fibrosis. Eur J Med Res. 2002 ; 7: 79-80.
30. Ratjen F., Doring G., Nikolaizik WH Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. [see comment]. Lancet. 2001 ; 358: 983-984.
31. Prince AS Biofilms, antimicrobial resistance, and airway infection. N Engl J Med. 2002 ; 347: 1110-1111.
32. Costerton JW, Stewart PS, Greenberg EP Bacterial biofilms: a common cause of persistent infections. Science. 1999 ; 284: 1318-1322.
33. Hoiby N. Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis. Paediatric Drugs. 2000 ; 2: 451-463.
34. LiPuma JJ Burkholderia and emerging pathogens in cystic fibrosis. Semin Respir Crit Care Med. 2003 ; 24: 681-692.
35. Kalish LA, Waltz DA, Dovey M., et al. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am J Respir Crit Care Med. 2006 ; 173: 421-425.
36. Coenye T., Vandamme P., Govan JR, LiPuma JJ Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol. 2001 ; 39: 3427-3436.
37. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev. 1996 ; 60: 539-574.
38. LiPuma JJ Burkholderia cepacia. Management issues and new insights. Clin Chest Med. 1998 ; 19: 473-486.
39. Cystic Fibrosis Foundation Patient Registry. Paper presented at: 2004 Annual Data Report to the Center Directors ; October 2005 ; Bethesda, MD.
40. Isles A., Maclusky I., Corey M., et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr. 1984 ; 104: 206-210.
41. Mahenthiralingam E., Vandamme P., Campbell ME, et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis. 2001 ; 33: 1469-1475.
42. Goss CH, Mayer-Hamblett N., Aitken ML, Rubenfeld GD, Ramsey BW Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. [see comment]. Thorax. 2004 ; 59: 955-959.
43. Olivier KN, Weber DJ, Wallace RJ Jr, et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. [see comment]. Am J Respir Crit Care Med. 2003 ; 167: 828-834.
44. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: cystic fibrosis foundation consensus conference. Clin Infect Dis. 2003 ; 37: S225 - S264.
45. Jung A., Kleinau I., Schonian G., et al. Sequential genotyping of Pseudomonas aeruginosa from upper and lower airways of cystic fibrosis patients. Eur Respir J. 2002 ; 20: 1457-1463.
46. Henig NR, Tonelli MR, Pier MV, Burns JL, Aitken ML Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis. Thorax. 2001 ; 56: 306-311.
47. Rosenfeld M., Emerson J., Accurso F., et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. [see comment]. Pediatr Pulmonol. 1999 ; 28: 321-328.
48. Sood N., Paradowski LJ, Yankaskas JR Outcomes of intensive care unit care in adults with cystic fibrosis. [see comment]. Am J Respir Crit Care Med. 2001 ; 163: 335-338.
49. Ramsey BW Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med. 1996 ; 335: 179-188.
50. Noone PG, Knowles MR Standard therapy of CF lung disease. Philadelphia, PA: Lippincott-Raven ; 1999.
51. Saiman L., Chen Y., Tabibi S., et al. Identification and antimicrobial susceptibility of alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J Clin Microbiol. 2001 ; 39: 3942-3945.
52. Saiman L., Mehar F., Niu WW, et al. Antibiotic susceptibility of multiply resistant pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis. 1996 ; 23: 532-537.
53. Burns JL, Saiman L. Burkholderia cepacia infections in cystic fibrosis. Pediatr Infect Dis J. 1999 ; 18: 155-156.
54. Aaron SD, Ferris W., Henry DA, Speert DP, Macdonald NE Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med. 2000 ; 161: 1206-1212.
55. Ebert DL, Olivier KN Nontuberculous mycobacteria in the setting of cystic fibrosis. Clin Chest Med. 2002 ; 23: 655-663.
56. Kearns GL, Trang JM Introduction to pharmacokinetics: aminoglycosides in cystic fibrosis as a prototype. J Pediatr. 1986 ; 108: 847-853.
57. Beringer PM, Vinks AA, Jelliffe RW, Shapiro BJ Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. J Antimicrob Chemother. 2000 ; 44: 809-813.
58. Karlowsky JA, Zhanel GG, Davidson RJ, Hoban DJ Postantibiotic effect in pseudomonas aeruginosa following single and multiple aminoglycoside exposures in vitro. J Antimicrob Chemother. 1994 ; 33: 937-947.
59. Saiman L., Siegel J. Cystic fibrosis foundation consensus conference on infection control P. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control. 2003 ; 31: S1 - S62.
60. Rosenfeld M., Joy P., Nguyen CD, Krzewinski J., Burns JL Cleaning home nebulizers used by patients with cystic fibrosis: is rinsing with tap water enough ? J Hosp Infect. 2001 ; 49: 229-230.
61. McIlwaine MP, Davidson AG Airway clearance techniques in the treatment of cystic fibrosis. Curr Opin Pulm Med. 1996 ; 2: 447-451.
62. van der Schans C., Prasad A., Main E. Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis. Cochrane Database Syst Rev. 2000 ;( 2 ):CD001401. doi: 10.1002/14651858.
63. Main E., Prasad A., Schans C. Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis. Cochrane Database Syst Rev. 2005 ;( 1 ):CD002011. doi: 10.1002/14651858.
64. Weinberger M. Airways reactivity in patients with CF. Clin Rev Allergy Immunol. 2002 ; 23: 77-85.
65. Halfhide C., Evans HJ, Couriel J. Inhaled bronchodilators for cystic fibrosis. Cochrane Database Syst Rev. 2005 ;( 4 ):CD003428. doi: 10.1002/14651858.
66. Shak S., Capon DJ, Hellmiss R., Marsters SA, Baker CL Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci U S A. 1990 ; 87: 9188-9192.
67. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The pulmozyme study group.[see comment]. N Engl J Med. 1994 ; 331: 637-642.
68. Jones AP, Wallis CE Recombinant human deoxyribonuclease for cystic fibrosis.. Cochrane Database Syst Rev. 2003 ;( 3 ):CD001127. doi: 10.1002/14651858.
69. Slattery DM, Waltz DA, Denham B., O'Mahony M., Greally P. Bronchoscopically administered recombinant human DNase for lobar atelectasis in cystic fibrosis. Pediatr Pulmonol. 2001 ; 31: 383-388.
70. Shah PL, Scott SF, Hodson ME Lobar atelectasis in cystic fibrosis and treatment with recombinant human DNase I. Respir Med. 1994 ; 88: 313-315.
71. Denton R., Kwart H., Litt M. N-acetylcysteine in cystic fibrosis. Mechanical and chemical factors in treatment by aerosol. Am Rev Respir Dis. 1967 ; 95: 643-651.
72. Duijvestijn YC, Brand PL Systematic review of N-acetylcysteine in cystic fibrosis. Acta Paediatrica. 1999 ; 88: 38-41.
73. Auerbach HS, Williams M., Kirkpatrick JA, Colten HR Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet. 1985 ; 2: 686-688.
74. Eigen H., Rosenstein BJ, FitzSimmons S., Schidlow DV A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. cystic fibrosis foundation prednisone trial group. J Pediatr. 1995 ; 126: 515-523.
75. Ichimiya T., Takeoka K., Hiramatsu K., Hirai K., Yamasaki T., Nasu M. The influence of azithromycin on the biofilm formation of pseudomonas aeruginosa in vitro. Chemotherapy. 1996 ; 42: 186-191.
76. Labro MT Anti-inflammatory activity of macrolides: a new therapeutic potential ? J Antimicrob Chemother. 1998 ; 41: 37-46.
77. Konstan MW, Byard PJ, Hoppel CL, Davis PB Effect of high-dose ibuprofen in patients with cystic fibrosis. [see comment]. N Engl J Med. 1995 ; 332: 848-854.
78. Saiman L., Marshall BC, Mayer-Hamblett N., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003 ; 290: 1749-1756.
79. Saiman L., Mayer-Hamblett N., Campbell P., Marshall BC ; and the Macrolide Study Group. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med. 2005 ; 172: 1008-1012.
80. Wolter J., Seeney S., Bell S., Bowler S., Masel P., McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax. 2002 ; 57: 212-216.
81. Equi A., Balfour-Lynn IM, Bush A., Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. [see comment]. Lancet. 2002 ; 360: 978-984.
82. Tepper RS, Skatrud JB, Dempsey JA Ventilation and oxygenation changes during sleep in cystic fibrosis. Chest. 1983 ; 84: 388-393.
83. Muller NL, Francis PW, Gurwitz D., Levison H., Bryan AC Mechanism of hemoglobin desaturation during rapid-eye-movement sleep in normal subjects and in patients with cystic fibrosis. Am Rev Respir Dis. 1980 ; 121: 463-469.
84. Gozal D. Nocturnal ventilatory support in patients with cystic fibrosis: comparison with supplemental oxygen. Eur Respir J. 1997 ; 10: 1999-2003.
85. Milross MA, Piper AJ, Norman M., et al. Low-flow oxygen and bilevel ventilatory support: effects on ventilation during sleep in cystic fibrosis. Am J Respir Crit Care Med. 2001 ; 163: 129-134.
86. Fauroux B., Boule M., Lofaso F., et al. Chest physiotherapy in cystic fibrosis: improved tolerance with nasal pressure support ventilation. Pediatrics. 1999 ; 103: E32.
87. Holland AE, Denehy L., Ntoumenopoulos G., Naughton MT, Wilson JW Non-invasive ventilation assists chest physiotherapy in adults with acute exacerbations of cystic fibrosis. Thorax. 2003 ; 58: 880-884.
88. Moran F., Bradley J. Non-invasive ventilation for cystic fibrosis. Cochrane Database Syst Rev. 2003 ;( 2 ):CD002769. doi: 10.1002/14651858.
89. Davis PB, di Sant'Agnese PA Assisted ventilation for patients with cystic fibrosis. JAMA. 1978 ; 239: 1851-1854.
90. Ellaffi M., Vinsonneau C., Coste J., et al. One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis. Am J Respir Crit Care Med. 2005 ; 171: 158-164.
91. Schidlow DV, Taussig LM, Knowles MR Cystic fibrosis foundation consensus conference report on pulmonary complications of cystic fibrosis. Pediatr Pulmonol. 1993 ; 15: 187-198.
92. Brinson GM, Noone PG, Mauro MA, et al. Bronchial artery embolization for the treatment of hemoptysis in patients with cystic fibrosis. Am J Respir Crit Care Med. 1998 ; 157: 1951-1958.
93. Chang AB, Ditchfield M., Robinson PJ, Robertson CF Major hemoptysis in a child with cystic fibrosis from multiple aberrant bronchial arteries treated with tranexamic acid. Pediatr Pulmonol. 1996 ; 22: 416-420.
94. Wong LT, Lillquist YP, Culham G., DeJong BP, Davidson AG Treatment of recurrent hemoptysis in a child with cystic fibrosis by repeated bronchial artery embolizations and long-term tranexamic acid. Pediatr Pulmonol. 1996 ; 22: 275-279.
95. Flume PA Pneumothorax in cystic fibrosis. Chest. 2003 ; 123: 217-221.
96. Penketh AR, Knight RK, Hodson ME, Batten JC Management of pneumothorax in adults with cystic fibrosis. Thorax. 1982 ; 37: 850-853.
97. Phillips GD, Trotman-Dickenson B., Hodson ME, Geddes DM Role of CT in the management of pneumothorax in patients with complex cystic lung disease. Chest. 1997 ; 112: 275-278.
98. Arcasoy SM, Kotloff RM Lung transplantation. N Engl J Med. 1999 ; 340: 1081-1091.
99. Kerem E., Reisman J., Corey M., Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. [see comment]. N Engl J Med. 1992 ; 326: 1187-1191.
100. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001 ; 153: 345-352.
101. Liou TG, Adler FR, Huang D. Use of lung transplantation survival models to refine patient selection in cystic fibrosis. Am J Respir Crit Care Med. 2005 ; 171: 1053-1059.
102. Meyers BF, Lynch J., Trulock EP, Guthrie TJ, Cooper JD, Patterson GA Lung transplantation: a decade of experience [discussion]. Ann Surg. 1999 ; 230: 361-370.
103. Mallory GB, Spray TL Paediatric lung transplantation. Eur Respir J. 2004 ; 24: 839-845.
104. Choong CK, Sweet SC, Zoole JB, et al. Bronchial airway anastomotic complications after pediatric lung transplantation: incidence, cause, management, and outcome. J Thorac Cardiovasc Surg. 2006 ; 131: 198-203.
105. Bech B., Pressler T., Iversen M., et al. Long-term outcome of lung transplantation for cystic fibrosis-Danish results. Eur J Cardiothorac Surg. 2004 ; 26: 1180-1186.
106. Goudarzi BM, Bonvino S. Critical care issues in lung and heart transplantation. Crit Care Clin. 2003 ; 19: 209-231.
107. Lau CL, Patterson GA Current status of lung transplantation. Eur Respir J Suppl. 2003 ; 47: 57s - 64s.
108. Ahya VN, Kawut SM Noninfectious pulmonary complications after lung transplantation. Clin Chest Med. 2005 ; 26: 613-622.
109. Lau CL, Patterson GA, Palmer SM Critical care aspects of lung transplantation. J Intensive Care Med. 2004 ; 19: 83-104.
110. Guilinger RA, Paradis IL, Dauber JH, et al. The importance of bronchoscopy with transbronchial biopsy and bronchoalveolar lavage in the management of lung transplant recipients. Am J Respir Crit Care Med. 1995 ; 152: 2037-2043.
111. Mallory GB Jr. Inflammation in lung transplantation for CF. Immunosuppression and modulation of inflammation. Clin Rev Allergy Immunol. 2002 ; 23: 105-122.
112. Chhajed PN, Aboyoun C., Chhajed TP, et al. Sedative drug requirements during bronchoscopy are higher in cystic fibrosis after lung transplantation. Transplantation. 2005 ; 80: 1081-1085.
113. Boehler A. Update on cystic fibrosis: selected aspects related to lung transplantation. Swiss Med Wkly. 2003 ; 133: 111-117.
114. Lamireau T., Monnereau S., Martin S., Marcotte J-E., Winnock M., Alvarez F. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J Hepatol. 2004 ; 41: 920.
115. Williams SM, Goodman R., Thomson A., McHugh K., Lindsell DR Ultrasound evaluation of liver disease in cystic fibrosis as part of an annual assessment clinic: a 9-year review. Clin Radiol. 2002 ; 57: 365-370.
116. Curry MP, Hegarty JE The gallbladder and biliary tract in cystic fibrosis. Curr Gastroenterol Rep. 2005 ; 7: 147-153.
117. Colombo C., Apostolo MG, Ferrari M., et al. Analysis of risk factors for the development of liver disease associated with cystic fibrosis. [see comment]. J Pediatr. 1994 ; 124: 393-399.
118. Stewart L. The role of abdominal ultrasound in the diagnosis, staging and management of cystic fibrosis liver disease. J R Soc Med. 2005 ; 98: 17-27.
119. Gilljam M., Ellis L., Corey M., Zielenski J., Durie P., Tullis DE Clinical manifestations of cystic fibrosis among patients with diagnosis in adulthood. Chest. 2004 ; 126: 1215-1224.
120. Poupon RE, Poupon R., Balkau B., The U-PBCSG. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med. 1994 ; 330: 1342-1347.
121. Debray D., Lykavieris P., Gauthier F., et al. Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension. J Hepatol. 1999 ; 31: 77-83.
122. Mack DR, Traystman MD, Colombo JL, et al. Clinical denouement and mutation analysis of patients with cystic fibrosis undergoing liver transplantation for biliary cirrhosis. J Pediatr. 1995 ; 127: 881-887.
123. Milkiewicz P., Skiba G., Kelly D., et al. Transplantation for cystic fibrosis: outcome following early liver transplantation. J Gastroenterol Hepatol. 2002 ; 17: 208-213.
124. Dobson L., Sheldon CD, Hattersley AT Understanding cystic-fibrosis- related diabetes: best thought of as insulin deficiency ? J R Soc Med. 2004 ; 97: 26-35.
125. Hardin DS, Leblanc A., Marshall G., Seilheimer DK Mechanisms of insulin resistance in cystic fibrosis. Am J Physiol Endocrinol Metab. 2001 ; 281: E1022-1028.
126. Costa M., Potvin S., Berthiaume Y., et al. Diabetes: a major co-morbidity of cystic fibrosis. Diabetes Metab. 2005 ; 31: 221-232.
127. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med. 2000 ; 162: 891-895.
128. Egi M., Bellomo R., Stachowski E., et al. Intensive insulin therapy in postoperative intensive care unit patients: a decision analysis. Am J Respir Crit Care Med. 2006 ; 173: 407-413.
129. Fridell JA, Vianna R., Kwo PY, et al. Simultaneous liver and pancreas transplantation in patients with cystic fibrosis. Transplant Proc. 2005 ; 37: 3567-3569.
130. Dobson L., Stride A., Bingham C., Elworthy S., Sheldon CD, Hattersley AT Microalbuminuria as a screening tool in cystic fibrosis-related diabetes. Pediatr Pulmonol. 2005 ; 39: 103-107.
131. McKeon DJ, Haworth C., Bradley JR, Bilton D. Cystic fibrosis pulmonary disease is not a contra-indication to live-related renal transplantation. Nephrol Dial Transplant. 2005 ; 20: 664.
132. Stern RC, Mayes JT, Weber FL Jr, Blades EW, Schulak JA Restoration of exocrine pancreatic function following pancreas-liver-kidney transplantation in a cystic fibrosis patient. Clin Transplant. 1994 ; 8: 1-4.
133. Baker SS, Borowitz D., Baker RD Pancreatic exocrine function in patients with cystic fibrosis. Curr Gastroenterol Rep. 2005 ; 7: 227-233.
134. Dray X., Bienvenu T., Desmazes-Dufeu N., Dusser D., Marteau P., Hubert D. Distal intestinal obstruction syndrome in adults with cystic fibrosis. Clin Gastroenterol Hepatol. 2004 ; 2: 498-503.
135. Eggermont E. Gastrointestinal manifestations in cystic fibrosis. Eur J Gastroenterol Hepatol. 1996 ; 8: 731-738.
136. Navarro O., Dugougeat F., Kornecki A., Shuckett B., Alton DJ, Daneman A. The impact of imaging in the management of intussusception owing to pathologic lead points in children. A review of 43 cases. Pediatr Radiol. 2000 ; 30: 594-603.
137. Turner D., Rickwood AM, Brereton RJ Intussusception in older children. Arch Dis Child. 1980 ; 55: 544-546.
138. Holmes M., Murphy V., Taylor M., Denham B. Intussusception in cystic fibrosis. Arch Dis Child. 1991 ; 66: 726-727.
139. Khera G., Kumarage S., Strekozov B. Adult intussusception in a cystic fibrosis patient-mimicking acute appendicitis. ANZ J Surg. 2004 ; 74: 807-808.
140. Wilschanski M., Fisher D., Hadas-Halperin I., et al. Findings on routine abdominal ultrasonography in cystic fibrosis patients. J Pediatr Gastroenterol Nutr. 1999 ; 28: 182-185.
141. Minkes RK, Langer JC, Skinner MA, et al. Intestinal obstruction after lung transplantation in children with cystic fibrosis. J Pediatr Surg. 1999 ; 34: 1489-1493.
142. De Boeck K., Weren M., Proesmans M., Kerem E. Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype. Pediatrics. 2005 ; 115: e463 - e469.
143. Rowntree RK, Harris A. The phenotypic consequences of CFTR mutations. Ann Hum Genet. 2003 ; 67: 471-485.
144. Pencharz PB, Durie PR Pathogenesis of malnutrition in cystic fibrosis, and its treatment. Clin Nutr. 2000 ; 19: 387-394.
145. Pencharz P., Hill R., Archibald E., Levy L., Newth C. Energy needs and nutritional rehabilitation in undernourished adolescents and young adult patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 1984 ; 3: S147 - S153.
146. Massie RJ, Towns SJ, Bernard E., Chaitow J., Howman-Giles R., Van Asperen PP The musculoskeletal complications of cystic fibrosis. J Paediatr Child Health. 1998 ; 34: 467-470.
147. Parasa RB, Maffulli N. Musculoskeletal involvement in cystic fibrosis. Bull Hosp Joint Dis. 1999 ; 58: 37-44.
148. Aris RM, Renner JB, Winders AD, et al. Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann Intern Med. 1998 ; 128: 186-193.
149. Freyer DR Care of the dying adolescent: special considerations. Pediatrics. 2004 ; 113: 381-388.
150. Robinson WM, Ravilly S., Berde C., Wohl ME End-of-life care in cystic fibrosis. [see comment]. Pediatrics. 1997 ; 100: 205-209.
151. Aurora P., Lynn IM Lung transplantation and end of life issues in cystic fibrosis. Paediatr Respir Rev. 2000 ; 1: 114-120.
152. Meyer EC, Ritholz MD, Burns JP, Truog RD Improving the quality of end-of-life care in the pediatric intensive care unit: parents' priorities and recommendations. Pediatrics. 2006 ; 117: 649-657.
153. Meisel A., Snyder L., Quill T., American college of physicians-american society of internal medicine end-of-life care consensus P. Seven legal barriers to end-of-life care: myths, realities, and grains of truth. JAMA. 2000 ; 284: 2495-2501.